| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-06-13 | Avacta (UK) Mologic (UK) | diagnostic tests using Avacta’s Affimer technology | R&D development |
Diagnostic | R&D agreement | |
| 2016-06-13 | Eurofins Scientific (France) | Dungarvan, Ireland campus | construction of new premises | Technology - Services | Construction of new premises | |
| 2016-06-10 | Amicus Therapeutics (USA - NJ) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-06-09 | Bluebird bio (USA - MA) Lonza (Switzerland) | Lenti-D™ and LentiGlobin™ drug products | manufacturing production |
Technology - Services | Production agreement | |
| 2016-06-08 | Abbvie (USA - IL) Infinity Pharmaceuticals (USA - MA) | duvelisib (IPI-145) | development commercialisation |
Cancer - Oncology | Termination of the agreement | |
| 2016-06-08 | Crispr Therapeutics (Switzerland - USA - MA) Anagenesis Biotechnologies (France) | paraxial mesoderm multipotent cells (P2MCs) technology | all human muscle diseases including Duchenne muscular dystrophy (DMD) | collaboration, licensing | Rare diseases - Genetic diseases - Neuromuscular diseases | Licensing agreement |
| 2016-06-07 | Molmed (Italy) Oxford BioMedica (UK) | LentiVector® platform technology patents | licensing |
Technology - Services | Licensing agreement | |
| 2016-06-07 | Tapimmune (USA - FL) Mayo Clinic (USA - MN) | HER2neu vaccine technology | breast cancer | exercise of an option agreement |
Cancer - Oncology | Exercise of an option agreement |
| 2016-06-07 | Cobra Biologics (Sweden) Touchlight (UK) | Adeno-Associated Virus (AAV) vectors used in the delivery of gene therapy treatments | collaboration development |
Technology - Services | Collaboration agreement | |
| 2016-06-07 | Xbrane Biopharma (Sweden) Biotechpharma (Sweden) | Xbrane (biosimilar ranibizumab ) biosimilar version of Lucentis® | production manufacturing |
Ophtalmological diseases | Production agreement | |
| 2016-06-06 | Fujifilm Diosynth Biotechnologies (USA - NC) Merck&Co (USA - NJ) | large-scale microbial-biologics facility | collaboration production manufacturing |
Technology - Services | Collaboration agreement | |
| 2016-06-06 | CEVEC Pharmaceuticals (Germany) Paragon Bioservices (USA - MD) | CAP® technologies including CAP® GT expression system for gene therapy and CAP®Go for glycoproteins | collaboration production manufacturing |
Technology - Services | Collaboration agreement | |
| 2016-06-06 | Moderna Therapeutics (USA - MA) Charles River (USA - MA) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2016-06-06 | Alder Biopharmaceuticals (USA - WA) | nomination | CNS diseases - Neurological diseases | Nomination | ||
| 2016-06-05 | Sanofi (France) DiCE Molecules (USA - CA) | up to 12 discrete targets | R&D |
R&D agreement | ||
| 2016-06-03 | ViiV Healthcare (UK - USA) Botswana Ministry of Health | dolutegravir | HIV infection | collaboration |
Infectious diseases | Collaboration agreement |
| 2016-06-02 | Oxford BioMedica (UK) Green Cross LabCell (South Korea) | gene modified natural killer (NK) cell-based therapeutics/CAR-NK cell-based products | R&D |
Cancer - Oncology | R&D agreement | |
| 2016-06-02 | Arsanis (USA - MA) | nomination |
Infectious diseases | Nomination | ||
| 2016-06-02 | Ariad Pharmaceuticals (USA - MA) Incyte (USA - DE) | Iclusig™ (ponatinib) and Ariad's european operations | product acquisition licensing |
Product acquisition | ||
| 2016-06-02 | Ariad Pharmaceuticals (USA - MA) Incyte (USA - DE) | Iclusig™ (ponatinib) and Ariad's european operations | product acquisition licensing |
Product acquisition |
